Claritev Corp (CTEV) — Titan Protect Analysis

CTEV

Claritev Corp

Healthcare · ·

$25.84

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$442M

Total market value of the company

Trailing P/E

N/A

Forward P/E

3.79

Based on estimated future earnings — lower means cheaper

Rev Growth

+5.8%

Year-over-year revenue change

Profit Margin

-29.3%

How much profit the company keeps from each dollar of revenue

ROE

N/A

Return on equity — how efficiently it uses shareholder money

Analyst Target

$35.00

+35% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 6 analysts covering this stock

About Claritev Corp

Claritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers claims intelligence solutions, including reference-based pricing, negotiation services, surprise bill services, and Vistara; network solutions, such as primary networks, complementary networks, and network build and network management services; and payment and r

https://www.claritev.com

Country: United States Employees: 3,000 Industry: Health Information Services

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

0.828

Good returns relative to risk taken

Kelly Fraction

0.0727

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.320

Drawdown risk outweighs the returns — higher risk profile

Annual Return

26.1%

Historical annualised return based on price data

Max Drawdown

-81.4%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.77

Less volatile than the market — more defensive

52W High

$74.07

65% below the year high

52W Low

$11.50

125% above the year low

Avg Volume

154,438

Average daily shares traded — higher means easier to buy and sell

Short Ratio

9.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-17.33

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

N/A

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

73.2%

Revenue left after cost of goods — higher means pricing power

Operating Margin

7.6%

Profit from core operations before interest and tax

Free Cash Flow

$109M

Positive — the business generates more cash than it spends

Revenue (TTM)

$979M

Total revenue over the last 12 months

Net Income

$-286,523,008

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$90.00

Target Median

$35.00

Target Low

$22.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go